StockData
Aura Biosciences, Inc. logo

Aura Biosciences, Inc. (AURA) stock

AURANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$7.15−0.07 (-0.97%)

Close on Nov 17, 2026Market cap $741.49MP/E –Yield –

Aura Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aura Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$138.08M. For fiscal 2025 it was -$112.79M. The highest annual figure on record is -$22.21M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$112.79M–
FY2024Dec 31, 2024-$96.12M–
FY2023Dec 31, 2023-$84.99M–
FY2022Dec 31, 2022-$60.30M–
FY2021Dec 31, 2021-$35.25M–
FY2020Dec 31, 2020-$22.21M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$48.07M–
Q1 FY2026Mar 31, 2026-$34.87M–
Q4 FY2025Dec 31, 2025-$27.24M–
Q3 FY2025Sep 30, 2025-$27.91M–
Q2 FY2025Jun 30, 2025-$28.61M–
Q1 FY2025Mar 31, 2025-$29.04M–
Q4 FY2024Dec 31, 2024-$27.81M–
Q3 FY2024Sep 30, 2024-$23.23M–
Q2 FY2024Jun 30, 2024-$22.76M–
Q1 FY2024Mar 31, 2024-$22.31M–
Q4 FY2023Dec 31, 2023-$24.78M–
Q3 FY2023Sep 30, 2023-$20.49M–
Q2 FY2023Jun 30, 2023-$20.28M–
Q1 FY2023Mar 31, 2023-$19.44M–
Q4 FY2022Dec 31, 2022-$17.61M–
Q3 FY2022Sep 30, 2022-$16.06M–
Q2 FY2022Jun 30, 2022-$13.82M–
Q1 FY2022Mar 31, 2022-$12.81M–
Q4 FY2021Dec 31, 2021-$11.63M–
Q3 FY2021Sep 30, 2021-$8.90M–
Q2 FY2021Jun 30, 2021-$8.80M–
Q1 FY2021Mar 31, 2021-$5.93M–
Q4 FY2020Dec 31, 2020-$4.91M–
Q3 FY2020Sep 30, 2020-$3.63M–

More Aura Biosciences figures

See a number that looks wrong?